Vasculitis & polymyalgia rheumatica

Assessment of long-term organ damage and predictors of damage accrual in Behçet's syndrome: a 10-year longitudinal study using the Behçet's Syndrome Overall Damage Index

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

Organ damage in BS is associated with different factors depending on the disease stage: while demographic features, particularly non-Italian origin and older age, significantly predict the presence of damage at diagnosis, older age and corticosteroid therapy are associated with damage accrual in the long-term.

Study context

Population
Behçet's syndrome (BS) patients followed for at least six months, real-life cohort
Participants
155 patients
Outcome
Organ damage (BODI score ≥1) and damage accrual (ΔBODI ≥1 between timepoints)
Follow-up
10-year follow-up
Methodological detailssingle-centre, longitudinal, multivariable logistic regression
  • Single-centre
  • Longitudinal
  • Multivariable logistic regression

Main finding

As reported in the abstract

Damage at diagnosis

31.1%

Damage at 10-year follow-up

53.8%

Damage accrual by 10-year follow-up

39.7%

Observational data: associations, not effects.

Further findings

Predictors of damage at baseline and of damage accrual (multivariable analysis)

Pre-existing damage at diagnosis was a risk factor for faster accumulation of new damage
Non-Italian origin and older age at diagnosis independent predictors of damage at baseline
Older age remained a significant predictor of damage accrual during 10-year follow-up
Accumulation of new damage associated with more frequent GC treatment

Original publication

Assessment of long-term organ damage and predictors of damage accrual in Behçet's syndrome: a 10-year longitudinal study using the Behçet's Syndrome Overall Damage Index. Clin Exp Rheumatol. Published 27 February 2026. doi:10.55563/clinexprheumatol/rk2h59

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.